Abbvie Inc. vs Regeneron Pharmaceuticals Inc
ABBV vs REGN — side-by-side comparison from reported financials. ABBV leads 4, REGN leads 7 of 11 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Regeneron Pharmaceuticals Inc
REGN · Healthcare
$745.55+0.81%Mixed
| Metric | ABBV | REGN |
|---|---|---|
| Price | $276.43 | $745.55 |
| Market cap | $488B | $76.8B |
| Revenue (TTM) | $64.4B | $15.5B |
| Revenue growth | +1.8% | +5.6% |
| Net margin | 9.8% | 27.9% |
| Free cash flow | $18.2B | $3.76B |
| Net cash (debt) | ($56.2B) | $6.62B |
| 1-year price return | +19.8% | +30.8% |
| P/E | 77.4 | 17.8 |
| P/E vs own history (cheap-side %) | 23% | 46% |
| Dividend yield | 2.45% | 0.49% |
| Return on equity | 96% | 14% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 10 of 11 |
| Employees | 57,000 | 15,410 |
Full résumé-style profiles: ABBV CV · REGN CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.